Article Text


Study protocol for a randomised, double-blinded, placebo-controlled, clinical trial of S-ketamine for pain treatment in patients with chronic pancreatitis (RESET trial)
  1. Jacob Juel1,
  2. Søren Schou Olesen1,
  3. Anne Estrup Olesen1,2,
  4. Jakob Lykke Poulsen1,
  5. Albert Dahan3,
  6. Oliver Wilder-Smith4,5,
  7. Adnan Madzak6,
  8. Jens Brøndum Frøkjær6,7,
  9. Asbjørn Mohr Drewes1,7
  1. 1Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark
  2. 2Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark
  3. 3Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands
  4. 4Department of Anesthesiology, Pain and Palliative Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
  5. 5Department of Health Science and Technology, Center for Sensory-Motor Interactions, Aalborg University, Aalborg, Denmark
  6. 6Mech-Sense, Department of Radiology, Aalborg University Hospital, Aalborg, Denmark
  7. 7Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
  1. Correspondence to Professor Asbjørn Mohr Drewes; amd{at}


Introduction Chronic pancreatitis (CP) is an inflammatory disease that causes irreversible damage to pancreatic tissue. Pain is its most prominent symptom. In the absence of pathology suitable for endoscopic or surgical interventions, pain treatment usually includes opioids. However, opioids often have limited efficacy. Moreover, side effects are common and bothersome. Hence, novel approaches to control pain associated with CP are highly desirable. Sensitisation of the central nervous system is reported to play a key role in pain generation and chronification. Fundamental to the process of central sensitisation is abnormal activation of the N-methyl-d-aspartate receptor, which can be antagonised by S-ketamine. The RESET trial is investigating the analgaesic and antihyperalgesic effect of S-ketamine in patients with CP.

Methods and analysis 40 patients with CP will be enrolled. Patients are randomised to receive 8 h of intravenous S-ketamine followed by oral S-ketamine, or matching placebo, for 4 weeks. To improve blinding, 1 mg of midazolam will be added to active and placebo treatment. The primary end point is clinical pain relief as assessed by a daily pain diary. Secondary end points include changes in patient-reported outcome measures, opioid consumption and rates of side effects. The end points are registered through the 4-week medication period and for an additional follow-up period of 8 weeks to investigate long-term effects. In addition, experimental pain measures also serves as secondary end points, and neurophysiological imaging parameters are collected. Furthermore, experimental baseline recordings are compared to recordings from a group of healthy controls to evaluate general aspects of pain processing in CP.

Ethics and dissemination The protocol is approved by the North Denmark Region Committee on Health Research Ethics (N-20130040) and the Danish Health and Medicines Authorities (EudraCT number: 2013-003357-17). The results will be disseminated in peer-reviewed journals and at scientific conferences.

Trial registration number The study is registered at (EudraCT number 2013-003357-17).


This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.